E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
|
E.1.1.1 | Medical condition in easily understood language |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Cancer [C04] |
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 21.0 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10015362 |
E.1.2 | Term | Esophageal cancer |
E.1.2 | System Organ Class | 100000004864 |
|
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
Investigating if a single treatment with electrochemotherapy debulks an esophageal tumors, thereby facilitating the patients’ ability to eat and drink, and also prolongs the interval before definitive stenting is required. Further investigate weather the effect lasts longer than the effect from argon plasma coagulation. |
|
E.2.2 | Secondary objectives of the trial |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
1. Male or female ≥18 years old. 2. Histological verified malignant tumor in the esophagus, including the GEJ. 3. Subjects must have been evaluated by an MDT and been considered unsuitable for potential curative treatment. 4. Subjects must not have received any previous oncological treatment due to this current cancer. 5. Performance status ECOG/WHO < 2. 6. Expected survival > 3 months. 7. Platelets ≥ 50 billion/l, International Normalized Ratio (INR) < 1,5 (medical correction is allowed, e.g. correction of a high INR using vitamin K). 8. Se-creatinine < 150 mole/l, (Cr-51-EDTA-clearance > 40 mL/min) are excluded. (Se-creatinine > 150 mole/l triggers a Cr-51-EDTA-clearence test). 9. Subjects must be willing and able to comply with the procedure such as agreed follow-up visits. 10. Sexually active women who can become pregnant should use adequate contraception during the trial (pill, spiral, injection of prolonged progestin, sub dermal implantation, hormone-containing vaginal devices, transdermal patches). 11. Subjects must give written informed consent.
|
|
E.4 | Principal exclusion criteria |
1. Coagulation disorder that cannot be corrected. 2. Subjects with renal dysfunction (Cr-51-EDTA-clearance < 40 mL/min are excluded). 3. Subjects with a clinically significant cardiac arrhythmia. 4. Pregnancy or lactation/breastfeeding. 5. Concurrent treatment with another investigational medicinal product. 6. Contraindications for use of bleomycin, including; acute pulmonary infection, severe pulmonary disease and allergic reactions to bleomycin observed in previous treatment. 7. Subjects who have previously undergone a regime of bleomycin with a cumulative dose of > 240.000 UI/m2. 8. Stenosis that prevents passage of the endoscope with the device attached. 9. Patients with any other clinical condition or prior therapy that, in the opinion of the investigator, would make the patient unsuitable for the study or unable to comply with the study requirements.
|
|
E.5 End points |
E.5.1 | Primary end point(s) |
Difference in Time-to-Interventional-Treatment-Demanding-stricture-related-Dysphagia (TITDD) between patients treated with electrochemotherapy and patients treated with argon plasma coagulation. |
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
It is registred when appearing or followed until death, maximum 2 years. |
|
E.5.2 | Secondary end point(s) |
Secondary outcomes include: dysphagia (Mellow Pinkas dysphagia score) pain (Visual Analog Scale, VAS) quality of life (QoL) (EORTC QLQ-C30) Adverse events (AEs) and Adverse reactions (ARs) tumor response evaluated from computed tomography (CT) tumor response evaluated from upper endoscopic exams 90 days survival 1 year survival
|
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
At day 7, months 1 and 3, and after 1 year. |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | Yes |
E.6.4 | Safety | No |
E.6.5 | Efficacy | No |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | Yes |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | Yes |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | No |
E.8.1.5 | Parallel group | No |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | Yes |
E.8.1.7.1 | Other trial design description |
Subjects are randomised to either electrochemotherapy (with bleomycin) or standard treatment. |
|
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | No |
E.8.2.3 | Other | Yes |
E.8.2.3.1 | Comparator description |
|
E.8.2.4 | Number of treatment arms in the trial | 2 |
E.8.3 |
The trial involves single site in the Member State concerned
| Yes |
E.8.4 | The trial involves multiple sites in the Member State concerned | No |
E.8.5 | The trial involves multiple Member States | No |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | No |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.7 | Trial has a data monitoring committee | No |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
Last visit of he last subject undergoing the trial. |
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | |
E.8.9.1 | In the Member State concerned months | |
E.8.9.1 | In the Member State concerned days | |